Department of Mathematics and Data Science Institute, Imperial College London, London, UK.
Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, UK.
Lancet Glob Health. 2017 Dec;5(12):e1221-e1234. doi: 10.1016/S2214-109X(17)30393-5. Epub 2017 Oct 11.
Contemporary data for causes of vision impairment and blindness form an important basis of recommendations in public health policies. Refreshment of the Global Vision Database with recently published data sources permitted modelling of cause of vision loss data from 1990 to 2015, further disaggregation by cause, and forecasts to 2020.
In this systematic review and meta-analysis, we analysed published and unpublished population-based data for the causes of vision impairment and blindness from 1980 to 2014. We identified population-based studies published before July 8, 2014, by searching online databases with no language restrictions (MEDLINE from Jan 1, 1946, and Embase from Jan 1, 1974, and the WHO Library Database). We fitted a series of regression models to estimate the proportion of moderate or severe vision impairment (defined as presenting visual acuity of <6/18 but ≥3/60 in the better eye) and blindness (presenting visual acuity of <3/60 in the better eye) by cause, age, region, and year.
We identified 288 studies of 3 983 541 participants contributing data from 98 countries. Among the global population with moderate or severe vision impairment in 2015 (216·6 million [80% uncertainty interval 98·5 million to 359·1 million]), the leading causes were uncorrected refractive error (116·3 million [49·4 million to 202·1 million]), cataract (52·6 million [18·2 million to 109·6 million]), age-related macular degeneration (8·4 million [0·9 million to 29·5 million]), glaucoma (4·0 million [0·6 million to 13·3 million]), and diabetic retinopathy (2·6 million [0·2 million to 9·9 million]). Among the global population who were blind in 2015 (36·0 million [12·9 million to 65·4 million]), the leading causes were cataract (12·6 million [3·4 million to 28·7 million]), uncorrected refractive error (7·4 million [2·4 million to 14·8 million]), and glaucoma (2·9 million [0·4 million to 9·9 million]). By 2020, among the global population with moderate or severe vision impairment (237·1 million [101·5 million to 399·0 million]), the number of people affected by uncorrected refractive error is anticipated to rise to 127·7 million (51·0 million to 225·3 million), by cataract to 57·1 million (17·9 million to 124·1 million), by age-related macular degeneration to 8·8 million (0·8 million to 32·1 million), by glaucoma to 4·5 million (0·5 million to 15·4 million), and by diabetic retinopathy to 3·2 million (0·2 million to 12·9 million). By 2020, among the global population who are blind (38·5 million [13·2 million to 70·9 million]), the number of patients blind because of cataract is anticipated to rise to 13·4 million (3·3 million to 31·6 million), because of uncorrected refractive error to 8·0 million (2·5 million to 16·3 million), and because of glaucoma to 3·2 million (0·4 million to 11·0 million). Cataract and uncorrected refractive error combined contributed to 55% of blindness and 77% of vision impairment in adults aged 50 years and older in 2015. World regions varied markedly in the causes of blindness and vision impairment in this age group, with a low prevalence of cataract (<22% for blindness and 14·1-15·9% for vision impairment) and a high prevalence of age-related macular degeneration (>14% of blindness) as causes in the high-income subregions. Blindness and vision impairment at all ages in 2015 due to diabetic retinopathy (odds ratio 2·52 [1·48-3·73]) and cataract (1·21 [1·17-1·25]) were more common among women than among men, whereas blindness and vision impairment due to glaucoma (0·71 [0·57-0·86]) and corneal opacity (0·54 [0·43-0·66]) were more common among men than among women, with no sex difference related to age-related macular degeneration (0·91 [0·70-1·14]).
The number of people affected by the common causes of vision loss has increased substantially as the population increases and ages. Preventable vision loss due to cataract (reversible with surgery) and refractive error (reversible with spectacle correction) continue to cause most cases of blindness and moderate or severe vision impairment in adults aged 50 years and older. A large scale-up of eye care provision to cope with the increasing numbers is needed to address avoidable vision loss.
Brien Holden Vision Institute.
当代有关视力损害和失明原因的数据为公共卫生政策提供了重要依据。利用最近发表的数据源更新全球视野数据库,可对 1990 年至 2015 年的视力丧失原因数据进行建模,进一步按病因细分,并预测至 2020 年。
在这项系统回顾和荟萃分析中,我们分析了 1980 年至 2014 年基于人群的视力损害和失明的原因的已发表和未发表的数据。我们通过在线数据库搜索,在 2014 年 7 月 8 日之前检索到基于人群的研究,这些数据库没有语言限制(从 1946 年 1 月 1 日开始的 MEDLINE 和从 1974 年 1 月 1 日开始的 Embase,以及世界卫生组织图书馆数据库)。我们拟合了一系列回归模型,以估计由各种原因、年龄、地区和年份导致的中度或重度视力障碍(定义为较好眼的视力低于 6/18,但≥3/60)和失明(较好眼的视力低于 3/60)的比例。
我们从 98 个国家的 288 项研究中确定了 3983541 名参与者的数据。在 2015 年全球中度或重度视力障碍人群中(2.166 亿[98.5 万至 3.591 亿]),主要病因是未矫正屈光不正(1.163 亿[4940 万至 2.021 亿])、白内障(5260 万[1820 万至 1.096 亿])、年龄相关性黄斑变性(840 万[0.9 万至 2.95 亿])、青光眼(400 万[0.6 万至 1.33 亿])和糖尿病性视网膜病变(260 万[0.2 万至 9.9 亿])。在 2015 年全球失明人群中(3600 万[1290 万至 6540 万]),主要病因是白内障(1260 万[340 万至 2.87 亿])、未矫正屈光不正(740 万[240 万至 1.48 亿])和青光眼(290 万[40 万至 9.9 亿])。到 2020 年,预计全球中度或重度视力障碍人群(2.371 亿[1.015 亿至 3.99 亿])中,未矫正屈光不正的人数将上升至 1.277 亿(5100 万至 2.253 亿),白内障将上升至 5710 万(1790 万至 1.241 亿),年龄相关性黄斑变性将上升至 880 万(80 万至 3.21 亿),青光眼将上升至 450 万(50 万至 1540 万),糖尿病性视网膜病变将上升至 320 万(20 万至 1290 万)。到 2020 年,全球失明人群(3850 万[1320 万至 7090 万])中,因白内障失明的人数预计将上升至 1340 万(330 万至 3160 万),因未矫正屈光不正失明的人数预计将上升至 800 万(250 万至 1.63 亿),因青光眼失明的人数预计将上升至 320 万(40 万至 1100 万)。白内障和未矫正屈光不正加在一起导致 2015 年 50 岁及以上成年人失明和视力障碍的比例分别为 55%和 77%。在这个年龄组中,世界各地区的失明和视力障碍原因差异很大,白内障的发病率较低(失明的发病率低于 22%,视力障碍的发病率为 14.1-15.9%),年龄相关性黄斑变性的发病率较高(高收入亚区失明的发病率超过 14%)。2015 年,所有年龄段因糖尿病视网膜病变(比值比 2.52[1.48-3.73])和白内障(1.21[1.17-1.25])导致的女性失明和视力障碍的发病率高于男性,而青光眼(0.71[0.57-0.86])和角膜混浊(0.54[0.43-0.66])导致的男性失明和视力障碍的发病率高于女性,且与性别无关与年龄相关性黄斑变性(0.91[0.70-1.14])。
由于人口增长和老龄化,导致视力丧失的常见原因的人数已大幅增加。可通过手术治疗的白内障(可逆)和屈光不正(可通过眼镜矫正)引起的可预防的视力丧失仍然是导致 50 岁及以上成年人中大多数失明和中度或重度视力障碍的原因。需要大规模扩大眼科护理服务,以应对不断增加的可避免的视力丧失。
布赖恩·霍顿视觉研究所。